| |
See The President's Message on 2005 & 2006
CVBT has a clear strategy for accomplishing its stated goal to become a commercially viable business. Our
strategy is based on developing a series of products for different medical
conditions associated with cardiovascular disease. Specifically, our
strategy calls for a specific series of steps towards growth and profitability of our core business:
- Obtain FDA approval of FGF-1141 for the
treatment of “Severe Coronary Heart Disease Patients” for sale in the U.S.
- Secure approval for reimbursement from third party payers.
- Implement commercial volume manufacturing capacity for FGF-1141.
- Market FGF-1141 to potential patients, focusing on patients with cardiovascular disease for whom no traditional medical treatment exists.
- Market to third party payers based on the anticipated economic benefit and improved quality of patient care offered by FGF-1141.
- Market to leading cardiac hospitals and physicians to have FGF-1141 adopted as “standard of care,” based on the anticipated economic benefits and improved patient care features of the product.
- Continue testing FGF-1141 in animal models for stroke, diabetic wounds, and peripheral artery disease, and to continue exploration for additional applications.
- After successful completion of animal studies, initiate clinical trials in patients receiving bypass surgery or other invasive coronary artery treatments as an adjunct to such treatments. We also plan to initiate clinical trials in patients with conditions such as peripheral artery disease, diabetic skin ulcers of legs and/or bed sores, stroke, and hypertensive renal disease.
- Finalize development of and obtain FDA approval for our catheter delivery system for FGF-1141.
< Back to CVBT Target Market
<< Return to CVBT Overview
Use of
this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics,
Inc.
All Rights Reserved.
Some content on this site requires the free Adobe Reader.
| |
